# A Computational Profiling of Changes in Gene Expression and Transcription Factors Induced by vFLIP K13 in Primary Effusion Lymphoma

Vasu Punj1,2, Hittu Matta1, Preet M. Chaudhary1*

1 From Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America, 2 Bioinformatics Core, Norris Comprehensive Cancer Center at USC Epigenome Center, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America

## Abstract

Infection with Kaposi’s sarcoma associated herpesvirus (KSHV) has been linked to the development of primary effusion lymphoma (PEL), a rare lymphoproliferative disorder that is characterized by loss of expression of most B cell markers and effusions in the body cavities. This unique clinical presentation of PEL has been attributed to their distinctive plasmablastic immunophenotype and clinical presentation that are characteristics of KSHV-associated PEL.

The K13 protein was originally thought to protect KSHV-infected cells from apoptosis by preventing the activation of caspase 8/FLICE and, as such, was classified as a viral FLICE inhibitory protein (vFLIP) [6]. However, subsequent work from our laboratory and others showed that K13 is a potent activator of the NF-κB pathway and manipulates this pathway to promote cellular survival, proliferation, transformation and cytokine secretion [7,8,9,10,11,12,13,14,15].

To understand how viruses subvert host molecular pathways and cause cellular transformation has been a fascinating and challenging task. The advent of microarray technology has made it feasible to perform whole genome expression profiling of different disease states [16]. In the conventional method microarray data analysis, only the top few individual genes that are highly differentially expressed between two phenotypes are analyzed [16]. Although such individual genes may prove to be relevant for KSHV infection, it is increasingly doubted whether large fold changes in individual genes have more biological relevance as compared to smaller but coordinated fold changes in a set of genes encoding proteins that belong to a single pathway [17]. As in biological processes, genes often cooperate in the so-called

## Introduction

Kaposi sarcoma-associated herpesvirus (KSHV) is directly associated with Kaposi sarcoma and several lymphoproliferative disorders (LPDs) including primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) [1]. PEL is a highly malignant plasmablastic tumor that most frequently affects body cavities such as the pericardial or pleural spaces [1]. This clonal B cell tumor is characterized by the lack of expression of most B and T cell markers and thus has a “null phenotype” [1]. PEL cells over-express genes involved in inflammation, cell adhesion and evasion, which is believed to contribute to their unique presentation in body cavities [2].

A hallmark of all herpesviruses is their ability to establish a lifelong latent infection. Five major KSHV proteins are present in the cells latently infected with the virus, including LANA (Latency associated nuclear antigen), vCyclin, vFLIP (viral FLICE inhibitory protein, also called K13), vIL6, and vIRF3 [3,4]. LANA, vCyclin and vFLIP K13 are transcribed from the same genomic region into a single tricistronic mRNA, which gets alternatively spliced into three transcripts [3]. The K13 gene encodes for a protein with homology to the prodomain of caspase 8/FLICE [6].

The K13 protein was originally thought to protect KSHV-infected cells from apoptosis by preventing the activation of caspase 8/FLICE and, as such, was classified as a viral FLICE inhibitory protein (vFLIP) [6]. However, subsequent work from our laboratory and others showed that K13 is a potent activator of the NF-κB pathway and manipulates this pathway to promote cellular survival, proliferation, transformation and cytokine secretion [7,8,9,10,11,12,13,14,15].

To understand how viruses subvert host molecular pathways and cause cellular transformation has been a fascinating and challenging task. The advent of microarray technology has made it feasible to perform whole genome expression profiling of different disease states [16]. In the conventional method microarray data analysis, only the top few individual genes that are highly differentially expressed between two phenotypes are analyzed [16]. Although such individual genes may prove to be relevant for KSHV infection, it is increasingly doubted whether large fold changes in individual genes have more biological relevance as compared to smaller but coordinated fold changes in a set of genes encoding proteins that belong to a single pathway [17]. As in biological processes, genes often cooperate in the so-called

---

**Citation:** Punj V, Matta H, Chaudhary PM (2012) A Computational Profiling of Changes in Gene Expression and Transcription Factors Induced by vFLIP K13 in Primary Effusion Lymphoma. PLoS ONE 7(5): e37498. doi:10.1371/journal.pone.0037498

**Editor:** Robert E. Means, Yale Medical School, United States of America

**Received** December 15, 2011; **Accepted** April 23, 2012; **Published** May 18, 2012

**Copyright:** © 2012 Punj et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by grants from the United States National Institutes of Health (DE019811 and CA139119). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: preet.chaudhary@med.usc.edu
Materials and Methods

Cell lines and reagents
293T and BCBL1 cells were obtained from the American Type Culture Collection. The IL-6 dependent murine T1165 plasmacloma cell line has been described earlier [23]. Polyclonal populations of BCBL1 cells expressing K13 and K13-ER^{TAM} have been described previously [21,24]. FLAG antibody was purchased from Calbiochem (San Diego, CA) and Arsenic trioxide (As_{2}O_{3}) was from Sigma-Altrich (St. Louis, MO).

Gene chip human array
We used the human genome HGU-133 plus 2.0 arrays (Affymetrix, Santa Clara, CA); an oligonucleotide-probe based gene array chip containing ~50,000 transcripts, which provides a comprehensive coverage of the whole human genome.

RNA isolation and hybridization to Gene arrays
BCBL1 cells stably expressing empty vector MSCV or MSCV K13-ER^{TAM} encoding constructs were treated with 4OHT (20 nM) or solvent for 48 h. Total RNA was isolated using Qiagen RNasey kit (Qiagen, Valencia, CA). Ten micrograms of total RNA was used to synthesize cDNA. T7 promoter introduced during the first strand synthesis was then used to direct cRNA synthesis, which was labeled with biotinylated deoxynucleotide triphosphate, following the manufacturer’s protocol (Affymetrix, San Diego, CA). After fragmentation, the biotinylated cRNA was hybridized to the gene chip array at 45°C for 16 h. The chip was washed, stained with phycocerythrin-streptavidin, and scanned with the Gene Chip Scanner 3000. After background correction, data analysis was done using PLIER16 (probe logarithmic intensity error) algorithm using Gene Spring GX11.0 (Agilent Technologies, Santa Clara, CA). The microarray data has been deposited with NCBI GEO database (GSE37355).

Luciferase reporter assay
A luciferase reporter plasmid containing the RANTES promoter was kindly provided by Dr. Robert Schleiner (Northwestern University). Expression constructs for K13 and K13-58AAA and phosphorylation-resistant mutants of IkBz have been described previously [7,26]. 293T cells were transfected in a 24-well plate with various test plasmids along with the RANTES luciferase reporter constructs (75 ng/well) and a pRSV/LacZ (β-galactosidase) reporter construct (75 ng/well), as described previously [27]. Cells were lysed 24-36 hours later, and cell extracts were used to measure firefly luciferase and β-galactosidase activities, respectively. Luciferase activity was normalized by the β-galactosidase activity to control for differences in transfection efficiency.

Gene set enrichment analysis (GSEA)
Nonparametric gene set enrichment analysis (GSEA) was performed using GSEA 2.0 (Broad Institute, Cambridge, MA) [19]. This method ranks genes according to their relative difference in expression (Student’s t-statistic) between two phenotypes of K13-ER^{TAM} cell (with and without 4OHT treatment). GSEA compares this ranked list of genes to a large collection of pathway data gene sets and assigns an enrichment score, if gene is present in the dataset its score is increased and if it is absent the score is decreased. The enrichment statistics is the maximum deviation of running enrichment score from zero. The gene sets that significantly perform the random-class permutations are considered significant. A significance threshold was set at a nominal p-value of 0.05 and a false discovery rate (FDR)<0.20, which is the estimated probability that a gene set with a given enrichment statistic represents a false-positive finding. The gene set with an FDR<0.20 indicates that the result is likely to be valid 9 out of 10 times.

Analysis of enrichment of Transcription Factor Binding sites (TFBS)
Transcription factor (TF) binding sites show the highest density around the transcription start site (TSS); therefore we restricted our analysis to 1000 bp upstream and downstream of TSS site. We used Biomat tool of Ensembl to retrieve 5’ flanking regions of each transcript. The conserved non-coding regions of the promoters were searched for matches to all TFBS profiles both in TRANSFAC [28] and JASPAR databases [29]. Briefly, while searching both databases in TELEs (Transcription Element Listening System), the parameters were set in order to set an FDR<20% (TRANSFEC) or <10% (JASPER) with corresponding p<0.01. We also validated the JASPAR and TRANSFAC predicted transcription factor binding sites in Matinspector of Genomatrix (Genomatrix, Munchen) as well as oPossum data bases [30].

Real-time PCR
cDNA was synthesized from RNA samples by PCR RNA core kit (Applied Biosystems, Bedford, MA). Real time quantitative reverse transcript-polymerase chain reaction (qRT-PCR) was performed with SYBER Green, using gene-specific PCR primers listed in Table S1. Samples were run in triplicate, and PCR was performed by an ABI Step One Plus thermocycler (Applied Biosystems, Bedford, MA). To take into consideration any change in the reference housekeeping gene, we used 4 representative reference genes (GNBL, β-2-microglobulin, GAPDH and 18S RNA) to calculate normalization factor (NF) using geNorm [31] module in qbase^{PLUS} software [32]. In addition, the efficiency (E)
of PCR in each run was also determined. Both NF and E were used to report relative expression of the gene of interest using 2^-ΔΔCT method as detailed earlier [33]. The statistical significance of expression was calculated by two sided paired t-test and Pearson Correlation coefficient between gene expression array and real time PCR was calculated using R statistical software.

Cell viability and cell-cycle assays
To study the biological activity of K13-induced IL6 secretion, the supernatants from untreated and 4OHT-treated BCBL1 cells expressing vector and K13-ERTAM cells were analyzed for the growth of IL-6 dependent T1165 cells. T1165 cells from exponentially growing cultures were washed three times with hIL6-free medium and plated in a flat-bottom 96-well plate at a density of 5×10^3 cells/well in the presence or absence of BCBL1 supernatants or hIL6. Cell viability was measured after 48 hours using the MTS reagent (3-(4,5-dimethylthiazol-2-y1)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) following manufacturer’s instructions (Promega, Madison, WI). Absorbance of viable cells was measured at 490 nm with 600 nm as a reference wavelength. Percent cell survival was calculated based on the reading of cells grown in the presence of hIL6 as 100%. DNA content analysis was performed as described previously [7]. Briefly, cell pellets were fixed in 70% ethanol, and incubated at 4°C overnight. For staining, the cell pellets were resuspended in 0.5 ml of 0.05 mg/ml Propidium Iodide (PI) plus 0.2 mg/ml RNAseA and incubated at 37°C for 30 minutes. Cell cycle distribution was analyzed on a BD Biosciences LSR II flow cytometry instrument.

Enzyme linked Immunosorbent assay (ELISA)
Human CCL5 (RANTES) was measured in the cell culture supernatant using a CCL5-ELISA kit from R&D systems (Minneapolis, MN) and following the recommendations of the manufacturer.

Results
Differential gene expression levels in BCBL1 -K13 cells
To study the impact of K13 on gene expression in PEL cells, we took advantage of the PEL-derived BCBL1 cells as they express negligible amount of K13 endogenously [24]. We had previously generated BCBL1 cells stably expressing a K13-ERTAM fusion construct in which K13 is fused in-frame to the ligand -binding domain of a mutated estrogen receptor [24]. The mutated estrogen receptor does not bind to its physiological ligand estrogen, but binds with very high affinity to the synthetic ligand 4OHT (4-hydroxytamoxifen) and regulates the activity of K13 in a 4OHT-dependent manner. The BCBL1 cells expressing either mock vector or K13-ERTAM were treated with 4OHT for 48 hours and RNA was harvested. High quality RNA was used to run gene expression array using Affymetrix HG-U133 plus 2 chip representing more than 50,000 annotated transcripts. Analysis of normalized fluorescence intensities indicated that in the cells expressing empty vector, expression ratios of most of the genes with and without 4OHT treatment remained close to 1 or changed slightly (≤2), suggesting that 4OHT by itself does not have any significant effect on gene expression. In contrast, induction of K13-ERTAM expression by 4OHT treatment changed the expression ratio of a significant proportion of genes more than 2 fold (data not shown). Next, the gene array data was uploaded to Gene Spring GX11.0 software, and after median shift normalization the primary analysis was performed using PLIER algorithm, as recommended in the workflow of the software. Table 1 enlists top 50 upregulated and 15 downregulated genes. Among the genes upregulated by K13 were several known NF-kB-responsive genes, such as BIRC3, TNFAIP3, EB13, NFkBIA, FAS, RELB and NFKB2. In contrast, CD19, a B cell marker was among the genes whose expression was down-regulated by K13. A complete list of genes differentially expressed in 4OHT-treated BCBL1-K13-ERTAM cells is provided as Table S2.

Pathway enrichment in K13 expressing cells
We used a unique approach of defining the various biological pathways affected by K13, where expression ratios of all the genes in the dataset were used to divide genes in various sets in terms of their biological relatedness. Gene set enrichment analysis (GSEA) using pathway definitions from Biocarta gene sets database revealed 9 significant gene sets specifically affected by K13 expression at a nominal p-value<0.05 and FDR<0.20. There are several well-known pathways affecting the cellular growth and cancer progression in these gene sets, such as Cytokine, Death, NF-kB and Inflammatory pathways (Table 2). In a complementary approach, GSEA using pathway definitions from Kyoto Encyclopedia of Genes and Genomes (KEGG) database revealed 10 gene sets significantly up-regulated in K13-expressing BCBL1 cells at a nominal p-value<0.05 and FDR<0.20. This analysis also identified several pathways linked to immune and inflammatory response and cell signaling, such as antigen processing and presentation, apoptosis, adipo-cytokine signaling, Toll like receptor signaling, cell adhesion molecules, epithelial cell signaling and cytokine-cytokine receptor interaction pathways (Table 2). Thus, despite the difference in definition of gene sets using the KEGG and Biocarta databases, the pathways identified to distinguish cellular responses attributed to K13 expression were comparable. These well accepted and widely used databases not only differ in their pathway definitions, but also offer different analyzable gene sets. For example, the newly discovered HIV-NEF, NKT and neutrophil-controlling FMLP pathways were not present, as such, in the KEGG database, which could probably explain why they were identified only in the GSEA using the Biocarta database.

Comparative Analysis of K13 induced genes in BCBL1 and HUVEC cells
We have previously generated K13-ERTAM expressing HUVEC and used them to study the effect of K13 on gene expression. We compared our newly generated gene expression data set of K13-ERTAM expressing BCBL1 with our publically available gene expression data set of K13-ERTAM expressing HUVEC (GSE16051) to determine if K13 affects genes differentially in different cell lineages, which could explain, in part, the distinct clinical presentations of clinical disorders associated with KSHV infection. Among the genes showing >2 fold induction following treatment with 4OHT, there were 42 genes that were shared between the BCBL1 and HUVEC data sets (Table S3). For example, Ubiquitin D was the most upregulated gene in 4OHT-treated BCBL1-K13-ERTAM cells and the second most upregulated gene in 4OHT treated HUVEC-K13-ERTAM cells. Additionally, genes belonging to the NF-kB, Cytokine and Inflammatory, HIV-NEF and NKT pathways were enriched in both datasets. Representative enrichment plots showing t-test for each correlated gene in the ranked dataset for Cytokine, NF-kB and inflammatory pathways are shown in Figure 1.

Although there was an overlap in the pathways activated by K13 in BCBL1 and HUVEC cells, there was a significant difference in the types and magnitude (fold induction) of genes induced by K13 in the two cell types. Thus, 4OHT treatment resulted in >20 fold induction of 14 genes in HUVEC-K13-
| S.No. | Entrez Gene | Gene Symbol | Gene Title | RefSeq Transcript ID | Fold change | Regulation |
|-------|-------------|-------------|------------|---------------------|-------------|------------|
| 1.    | 10537       | UBD         | ubiquitin D | NM_001470           | 26.07       | Up         |
| 2.    | 5328        | PLAU        | plasminogen activator, urokinase | NM_001145031 | 19.66       | Up         |
| 3.    | 5645        | PRSS2       | protease, serine, 2 (trypsin 2) | NM_002770 | 14.84       | Up         |
| 4.    | 330         | BIRC3       | baculoviral IAP repeat-containing 3 | NM_001165 | 13.51       | Up         |
| 5.    | 5644        | PRSS1       | protease, serine, 1 (trypsin 1) | NM_002769 | 13.24       | Up         |
| 6.    | 4050        | LTB         | lymphotxin beta (TNF superfamily, member 3) | NM_002341 | 12.98       | Up         |
| 7.    | 7128        | TNFAIP3     | tumor necrosis factor, alpha-induced protein 3 | NM_006290 | 12.85       | Up         |
| 8.    | 154754      | PRSS1       | protease, serine, 1 (trypsin 1) | NM_002769 | 12.56       | Up         |
| 9.    | 7262        | PHLD2       | pleckstrin homology-like domain, family A, member 2 | NM_003311 | 10.51       | Up         |
| 10.   | 10148       | EBI3        | Epstein-Barr virus induced 3 | NM_005755 | 9.90        | Up         |
| 11.   | 4914        | NTRK1       | neurotrophic tyrosine kinase, receptor, type 1 | NM_001007792 | 9.51       | Up         |
| 12.   | 6352        | CCL5        | chemokine (C-C motif) ligand 5 | NM_002985 | 9.42        | Up         |
| 13.   | 4792        | NFKBIA      | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | NM_020529 | 8.33        | Up         |
| 14.   | 2015        | EMR1        | egf-like module containing, mucin-like, hormone receptor-like 1 | NM_001974 | 8.10        | Up         |
| 15.   | 355         | FAS         | Fas (TNF receptor superfamily, member 6) | NM_000043 | 7.94        | Up         |
| 16.   | 972         | CD74        | CD74 molecule, major histocompatibility complex, class II invariant chain | NM_001025158 | 7.02        | Up         |
| 17.   | 3117        | HLA-DQA1    | major histocompatibility complex, class II, DQ alpha 1 | NM_002122 | 6.73        | Up         |
| 18.   | 259307      | IL4I1       | interleukin 4 induced 1 | NM_152899 | 6.58        | Up         |
| 19.   | 51700       | CYB5R2      | cytochrome b5 reductase 2 | NM_016229 | 6.44        | Up         |
| 20.   | 1543        | CYP1A1      | cytochrome P450, family 1, subfamily A, polypeptide 1 | NM_000499 | 6.01        | Up         |
| 21.   | 25907       | TMEM158     | transmembrane protein 158 | NM_015444 | 5.81        | Up         |
| 22.   | 7273        | TTN         | Titin       | NM_003319 | 5.21        | Up         |
| 23.   | 84033       | OBSCN       | obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF | NM_001098623 | 5.17        | Up         |
| 24.   | 7412        | VCAM1       | vascular cell adhesion molecule 1 | NM_001078 | 5.07        | Up         |
| 25.   | 9294        | S1PR2       | sphingosine-1-phosphate receptor 2 | NM_004230 | 5.03        | Up         |
| 26.   | 5971        | RELB        | v-rel reticuloendotheliosis viral oncogene homolog 8 | NM_006509 | 4.97        | Up         |
| 27.   | 5996        | RGS1        | regulator of G-protein signaling 1 | NM_002922 | 4.97        | Up         |
| 28.   | 9308        | CD83        | CD83 molecule | NM_001040280 | 4.94        | Up         |
| 29.   | 3383        | ICAM1       | intercellular adhesion molecule 1 | NM_000201 | 4.93        | Up         |
| 30.   | 25801       | GCA         | granulin, EF-hand calcium binding protein | NM_012198 | 4.92        | Up         |
| 31.   | 9235        | IL32        | interleukin 32 | NM_00102631 | 4.81        | Up         |
| 32.   | 8651        | SOCS1       | suppressor of cytokine signaling 1 | NM_003745 | 4.75        | Up         |
| 33.   | 11226       | GALNT6      | UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 6 | NM_007210 | 4.70        | Up         |
| 34.   | 1999        | ELF3        | E74-like factor 3 (ets domain transcription factor, epithelial-specific) | NM_001114309 | 4.68        | Up         |
| 35.   | 3109        | HLA-DMB     | major histocompatibility complex, class II, DM beta | NM_002118 | 4.50        | Up         |
| 36.   | 115019      | SLC26A9     | solute carrier family 26, member 9 | NM_001142600 | 4.49        | Up         |
| 37.   | 3561        | IL2RG       | interleukin 2 receptor, gamma (severe combined immunodeficiency) | NM_000206 | 4.48        | Up         |
| 38.   | 4261        | CIITA       | class II, major histocompatibility complex, transactivator | NM_000246 | 4.34        | Up         |
ERTAM cells (Table S4). In contrast, only one gene, Ubiquitin D, was induced 20 fold in 4OHT-treated BCBL1-K13-ERTAM cells (26.07 fold induction) (Table 1). Interestingly, although ubiquitin D was the most upregulated gene in BCBL1-K13-ERTAM cells and the second most upregulated gene in HUVEC-K13-ERTAM cells, there was a significant difference in the magnitude of induction (26.07 fold vs 61.02 fold) for this gene in the two cell types. Furthermore, a majority of genes whose expression was strongly induced by K13 in HUVECs were chemokines such as CCL2 (73.04 fold), CCL20 (63.8 fold), CCL5 (49.7 fold), CXCL10 (53.32 fold), IL8 (18.4 fold), CX3CL1 (30.48 fold) and IL6 (17.57 fold) (Table S4). In contrast, CCL5 (9.4 fold) and IL32 (4.8 fold) were the only chemokines whose expression was upregulated greater than 4-fold by K13 in BCBL1 cells (Table 1). Interestingly, suppressor of cytokine signaling 1 (SOCS1), a gene known to be involved in dampening of inflammatory response was upregulated 4.75 fold by K13 in BCBL1 cells but not in HUVECs (Table S4). Taken collectively, the above results demonstrate that although K13 activates the NF-κB pathway in both BCBL1 cells and HUVEC, it affects gene expression differentially in the two cell lineages and strongly upregulates genes belonging to proinflammatory chemokines mainly in HUVECs.

Transcriptional control of K13-induced gene expression

It has been well established that genes with common transcription factor (TF) binding sites have higher likelihood of sharing similar expression profiles [34,35]. Indeed, it is a widely accepted hypothesis that genes that are co-expressed share common regulatory motifs [36,37,38]. Therefore, we next examined if genes induced by 4OHT treatment in K13-ERTAM expressing BCBL1 and HUVECs were coordinately regulated by common TFs. For this purpose, we searched the JASPER database for TFs with binding sites over-represented in promoters of genes upregulated by K13 in BCBL1 and HUVECs. In the newly generated gene expression data set of 4OHT-treated BCBL1 K13-ERTAM expressing cells, there were 6 transcription factors whose binding sites were significantly over-represented in the promoters of K13-induced genes according to the JASPER database (p<0.01, FDR<0.10) (Table 3). Among these, three belonged to

### Table 1. Cont.

| S.No. | Entrez Gene | Gene Symbol | Gene Title | RefSeq Transcript ID | Fold change | Regulation |
|-------|-------------|-------------|------------|---------------------|-------------|------------|
| 39.   | 4791        | NFKB2       | nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | NM_001077493 | 4.29 | Up |
| 40.   | 718         | C3          | complement component 3 | NM_000064  | 4.29 | Up |
| 41.   | 285025      | CCDC141     | coiled-coil domain containing 141 | NM_173648  | 4.29 | Up |
| 42.   | 100132999   | LOC100132999| hypothetical protein LOC100132999 | NM_001722799 | 4.16 | Up |
| 43.   | 6892        | TAPBP       | TAP binding protein (tapasin) | NM_003190  | 4.14 | Up |
| 44.   | 6236        | RAD         | Ras-related associated with diabetes | NM_001128850 | 4.12 | Up |
| 45.   | 27074       | LAMP3       | lysosomal-associated membrane protein 3 | NM_014398  | 3.99 | Up |
| 46.   | 2232        | FDXR        | ferredoxin reductase | NM_004110  | 3.98 | Up |
| 47.   | 3119        | HLA-DQB1    | major histocompatibility complex, class II, DQ beta 1 | NM_002123  | 3.77 | Up |
| 48.   | 114294      | LACTB       | lactamase, beta | NM_032857  | 3.70 | Up |
| 49.   | 64319       | FBRS        | fiberin | NM_001105079 | 3.70 | Up |
| 50.   | 780         | DDR1        | discoidin domain receptor tyrosine kinase 1 | NM_001954  | 3.68 | Up |
| 51.   | 11124       | FAF1        | Fas (TNFRSF6) associated factor 1 | NM_007051  | 3.31 | Down |
| 52.   | 55916       | NXT2        | nuclear transport factor 2-like export factor 2 | NM_018698  | 2.74 | Down |
| 53.   | 51616       | TAF9B       | TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor | NM_015975  | 2.71 | Down |
| 54.   | 2162        | F13A1       | coagulation factor XIII, A1 polypeptide | NM_000129  | 2.63 | Down |
| 55.   | 3753        | KCNE1       | potassium voltage-gated channel, isk-related family, member 1 | NM_000219  | 2.53 | Down |
| 56.   | 55737       | VPS35       | vacuolar protein sorting 35 homolog (S. cerevisiae) | NM_018206  | 2.45 | Down |
| 57.   | 51474       | LIMA1       | LIM domain and actin binding 1 | NM_00113546 | 2.43 | Down |
| 58.   | 135932      | TMEM139     | transmembrane protein 139 | NM_153345  | 2.38 | Down |
| 59.   | 2844        | GPR21       | G protein-coupled receptor 21 | NM_005294  | 2.34 | Down |
| 60.   | 930         | CD19        | CD19 molecule | NM_001770  | 2.32 | Down |
| 61.   | 6711        | SPTBN1      | spectrin, beta, non-erythrocytic 1 | NM_003128  | 2.30 | Down |
| 62.   | 2744        | GLS         | Glutaminase | NM_014905  | 2.29 | Down |
| 63.   | 3890        | KRT84       | keratin 84 | NM_030405  | 2.23 | Down |
| 64.   | 54704       | PPM2C       | protein phosphatase 2C, magnesium-dependent, catalytic subunit | NM_018444  | 2.23 | Down |
| 65.   | 1131        | CHRM3       | cholinergic receptor, muscarinic 3 | NM_000740  | 2.22 | Down |

doi:10.1371/journal.pone.0037498.t001

ER \textsuperscript{TAM} cells (Table S4). In contrast, only one gene, Ubiquitin D, was induced 20 fold in 4OHT-treated BCBL1-K13-ER \textsuperscript{TAM} cells (26.07 fold induction) (Table 1). Interestingly, although ubiquitin D was the most upregulated gene in BCBL1-K13-ER \textsuperscript{TAM} cells and the second most upregulated gene in HUVEC-K13-ER \textsuperscript{TAM} cells, there was a significant difference in the magnitude of induction (26.07 fold vs 61.02 fold) for this gene in the two cell types. Furthermore, a majority of genes whose expression was strongly induced by K13 in HUVECs were chemokines such as CCL2 (73.04 fold), CCL20 (63.8 fold), CCL5 (49.7 fold), CXCL10 (53.32 fold), IL8 (18.4 fold), CX3CL1 (30.48 fold) and IL6 (17.57 fold) (Table S4). In contrast, CCL5 (9.4 fold) and IL32 (4.8 fold) were the only chemokines whose expression was upregulated greater than 4-fold by K13 in BCBL1 cells (Table 1). Interestingly, suppressor of cytokine signaling 1 (SOCS1), a gene known to be involved in dampening of inflammatory response was upregulated 4.75 fold by K13 in BCBL1 cells but not in HUVECs (Table S4). Taken collectively, the above results demonstrate that although K13 activates the NF-κB pathway in both BCBL1 cells and HUVEC, it affects gene expression differentially in the two cell lineages and strongly upregulates genes belonging to proinflammatory chemokines mainly in HUVECs.

Transcriptional control of K13-induced gene expression

It has been well established that genes with common transcription factor (TF) binding sites have higher likelihood of sharing similar expression profiles [34,35]. Indeed, it is a widely accepted hypothesis that genes that are co-expressed share common regulatory motifs [36,37,38]. Therefore, we next examined if genes induced by 4OHT treatment in K13-ER \textsuperscript{TAM} expressing BCBL1 and HUVECs were coordinately regulated by common TFs. For this purpose, we searched the JASPER database for TFs with binding sites over-represented in promoters of genes upregulated by K13 in BCBL1 and HUVECs. In the newly generated gene expression data set of 4OHT-treated BCBL1 K13-ER \textsuperscript{TAM} expressing cells, there were 6 transcription factors whose binding sites were significantly over-represented in the promoters of K13-induced genes according to the JASPER database (p<0.01, FDR<0.10) (Table 3). Among these, three belonged to
Table 2. Gene sets enriched in BCBL-K13 and HUVEC-K13 cells (a) Biocarta gene sets, (b) KEGG (Kyoto Encyclopedia of Genes and Genomes) gene sets.

| S.No. | Gene Set                          | No. of genes in set | ES   | NES   | NOMp-value | FDR q-value | RANKAT MAX |
|-------|-----------------------------------|---------------------|------|-------|------------|-------------|-------------|
| BCBL-K13 (a)-Biocarta                  |                     |                     |      |       |            |             |             |
| 1     | Cytokine pathway                  | 20                  | -0.70 | -1.82 | 0.007      | 0.087       | 1546        |
| 2     | Death pathway                     | 33                  | -0.62 | -1.79 | 0.000      | 0.066       | 1824        |
| 3     | NF-κB pathway                     | 23                  | -0.68 | -1.76 | 0.005      | 0.062       | 1824        |
| 4     | HIV Nef pathway                   | 55                  | -0.55 | -1.74 | 0.002      | 0.006       | 2079        |
| 5     | Inflammatory pathway              | 29                  | -0.61 | -1.71 | 0.005      | 0.072       | 1546        |
| 6     | NKT pathway                       | 26                  | -0.57 | -1.53 | 0.042      | 0.271       | 1709        |
| 7     | FMLP pathway                      | 35                  | -0.52 | -1.53 | 0.028      | 0.237       | 2728        |
| 8     | Stress pathway                    | 24                  | -0.56 | -1.51 | 0.025      | 0.240       | 3078        |
| 9     | NTHI pathway                      | 21                  | -0.59 | -1.50 | 0.049      | 0.227       | 2824        |
| BCBL-K13 (b)-KEGG                      |                     |                     |      |       |            |             |             |
| 1     | Antigen processing and presentation| 75                  | -0.62 | -2.06 | 0.000      | 0.002       | 1538        |
| 2     | Diabetes mellitus                 | 41                  | -0.65 | -1.92 | 0.000      | 0.010       | 2777        |
| 3     | Apoptosis                         | 83                  | -0.57 | -1.89 | 0.000      | 0.011       | 2661        |
| 4     | Adipocytokine signaling pathway   | 72                  | -0.56 | -1.86 | 0.000      | 0.015       | 3555        |
| 5     | Toll like receptor signaling path | 100                 | -0.51 | -1.76 | 0.000      | 0.041       | 2889        |
| 6     | Cell adhesion molecules           | 125                 | -0.49 | -1.74 | 0.000      | 0.044       | 3225        |
| 7     | Small cell lung cancer            | 87                  | -0.50 | -1.69 | 0.003      | 0.062       | 2889        |
| 8     | Thyroid cancer                    | 29                  | -0.59 | -1.62 | 0.014      | 0.107       | 3555        |
| 9     | Epithelial cell signaling         | 65                  | -0.47 | -1.54 | 0.009      | 0.200       | 560         |
| 10    | Cytokine cytokine receptor interaction| 244                 | -0.40 | -1.53 | 0.001      | 0.196       | 1950        |
| HUVEC-K13 (a)-Biocarta                 |                     |                     |      |       |            |             |             |
| 1     | Inflammatory pathway              | 29                  | -0.86 | -2.21 | 0.000      | 0.000       | 486         |
| 2     | Cytokine pathway                  | 20                  | -0.83 | -1.99 | 0.000      | 0.003       | 138         |
| 3     | IL-1Receptor pathway              | 31                  | -0.74 | -1.99 | 0.002      | 0.002       | 959         |
| 4     | NF-κB pathway                     | 23                  | -0.80 | -1.99 | 0.000      | 0.002       | 959         |
| 5     | DC pathway                        | 21                  | -0.78 | -1.92 | 0.002      | 0.008       | 224         |
| 6     | Toll pathway                      | 33                  | -0.68 | -1.81 | 0.006      | 0.029       | 1298        |
| 7     | NTHI pathway                      | 21                  | -0.76 | -1.80 | 0.002      | 0.029       | 959         |
| 8     | Death pathway                     | 33                  | -0.66 | -1.80 | 0.002      | 0.026       | 1712        |
| 9     | HIV NEF pathway                   | 55                  | -0.61 | -1.78 | 0.002      | 0.029       | 2101        |
| 10    | NKT pathway                       | 26                  | -0.69 | -1.75 | 0.013      | 0.036       | 800         |
| 11    | IL-6 pathway                      | 21                  | -0.70 | -1.72 | 0.011      | 0.042       | 1766        |
| 12    | IL-12 pathway                     | 20                  | -0.68 | -1.63 | 0.037      | 0.088       | 1446        |
| 13    | Raccycd pathway                   | 22                  | -0.62 | -1.59 | 0.045      | 0.112       | 928         |
| 14    | Stress pathway                    | 24                  | -0.60 | -1.51 | 0.074      | 0.180       | 949         |
| HUVEC-K13 (b)-KEGG                     |                     |                     |      |       |            |             |             |
| 1     | Cytokine cytokine receptor interaction| 244                 | -0.73 | -2.69 | 0.000      | 0.000       | 863         |
| 2     | Antigen processing and presentation| 75                  | -0.80 | -2.48 | 0.000      | 0.000       | 1246        |
| 3     | Toll like receptor signaling path | 100                 | -0.74 | -2.38 | 0.000      | 0.000       | 1053        |
| 4     | Epithelial cell signaling         | 65                  | -0.65 | -2.01 | 0.000      | 0.002       | 1170        |
| 5     | Diabetes mellitus                 | 41                  | -0.73 | -2.00 | 0.000      | 0.001       | 1192        |
| 6     | JAK STAT pathway                  | 151                 | -0.58 | -1.99 | 0.000      | 0.001       | 1766        |
| 7     | Cell adhesion molecules           | 125                 | -0.59 | -1.99 | 0.000      | 0.001       | 1025        |
Table 2. Cont.

| S.No. | Gene Set                        | No. of genes in set | ES  | NES  | NOMp-value | FDR q-value | RANKAT MAX |
|-------|--------------------------------|---------------------|-----|------|------------|-------------|------------|
| 8     | Hematopoietic cell lineage     | 84                  | −0.61 | −1.93 | 0.000      | 0.003       | 713        |
| 9     | Adipocytokine signaling pathway| 72                  | −0.60 | −1.84 | 0.000      | 0.010       | 1766       |
| 10    | Small cell lung cancer         | 87                  | −0.58 | −1.83 | 0.000      | 0.010       | 928        |
| 11    | Aminosugars metabolism         | 29                  | −0.66 | −1.69 | 0.019      | 0.051       | 1425       |
| 12    | Apoptosis                      | 83                  | −0.54 | −1.69 | 0.004      | 0.047       | 1161       |
| 13    | Natural killer cell mediated cytotoxicity | 127              | −0.49 | −1.65 | 0.004      | 0.062       | 2245       |
| 14    | T cell receptor signaling pathway | 93                | −0.49 | −1.59 | 0.004      | 0.101       | 1755       |

doi:10.1371/journal.pone.0037498.t002

Figure 1. Gene set enrichment analysis. For Gene set enrichment analysis of signatures genes from BCBL1-K13 (top panel) and HUVEC-K13 (lower panel), the t-test was graphed for each correlated gene in the ranked dataset. Three GSEA enrichment plots for representative biological pathways (Cytokine, NF-κB and Inflammatory) enriched in 4OHT-treated BCBL1-K13-ERTAM and HUVEC-K13-ERTAM are shown. The top portion of each GSEA plot shows the running enrichment score for validated genes specific for particular pathway as it moves down the ranked list. The bottom portion of each plot shows the value of ranking matrices as it moves down the list of ranked genes. The red horizontal bar which terminate with blue color indicate shift from positively correlated genes (red) to negatively correlated genes (blue). Further detailed interpretation about these plots can be found at Broad Institute web site (http://www.broadinstitute.org/gsea/index.jsp).
doi:10.1371/journal.pone.0037498.g001
Table 3. Transcription factors with binding sites over-represented in promoters of genes upregulated by K13 in BCBL1 and HUVECs.

| JASPAR database in BCBL1-K13 cells | TRANSFEC database in BCBL1-K13 cells | JASPAR database in HUVEC-K13 | TRANSFEC database in HUVEC-K13 |
|-------------------------------------|--------------------------------------|-----------------------------|--------------------------------|
| **S.No.** | **Sequence motif** | **Description** | **p-value** | **% of input** | **Sequence motif** | **Description** | **p-value** | **% of input** | **Sequence motif** | **Description** | **p-value** | **% of input** |
| 1 | Jaspar NF-kappaB | REL | 2.16E-6 | 29.6 | VSNFKAPPAB-01: NF-kappaB | NF-kappaB | 1.07E-5 | 27.7 | Jaspar c-REL | REL | 1.00E-10 | 37.8 |
| 2 | Jaspar p65 | REL | 0.0001 | 20.1 | VSNFKAPPAB65-01: NF-kappaB | NF-kappaB (p65) | 3.16E-5 | 24.5 | Jaspar NF-kappaB | REL | 3.99E-6 | 32.7 |
| 3 | Jaspar Irf-1 | TRP-cluster | 0.0025 | 17.6 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0002 | 17 | Jaspar Irf-1 | REL | 1.00E-10 | 26.5 |
| 4 | Jaspar CI-1USP | Nuclear receptor | 0.0027 | 16.4 | VSNFKB-Q6: NF-kappaB | NF-kappaB | 0.0001 | 12 | Jaspar p65 | REL | 1.00E-10 | 22.5 |
| 5 | Jaspar p50 | REL | 0.001 | 15.1 | VSIK3-01: Ik-3 | IkAROS 3 | 0.0012 | 8.8 | Jaspar Dorsal-2 | REL | 4.84E-6 | 20.4 |
| 6 | Jaspar COUP-TF | Nuclear receptor | 0.0030 | 4.4 | VSCOUP-01: COUP-TF | COUP/NF-4 heterodimer | 0.0031 | 3.0 | Jaspar p50 | REL | 0.0006 | 19.4 |
| 7 | Jaspar Irf-2 | TRP-cluster | 0.0088 | 2.6 | VSPAX2-01: Pax-2 | Pax-2 | 0.0024 | 2.6 | Jaspar c-FOS | bZIP | 0.0004 | 14.3 |
| 8 | Jaspar Brachyury | T-BOX | 0.0006 | 1.2 | VSNRFS-01: NRSF | neuron-restrictive silencer factor | 9.56E-6 | 1.2 | Jaspar Irf-2 | REL | 1.00E-10 | 11.2 |
| 9 | Jaspar COUP-TF | Nuclear receptor | 0.0088 | 1.1 | VSNFKAPPAB-01: NF-kappaB | NF-kappaB | 2.19E-6 | 38.7 | Jaspar Brachyury | T-BOX | 0.0006 | 1.2 |
| 10 | Jaspar c-FOS | bZIP | 0.0004 | 14.3 | VSNFKAPPAB65-01: NF-kappaB | NF-kappaB (p65) | 1.00E-10 | 28.6 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 |
| 11 | Jaspar Irf-2 | TRP-cluster | 1.00E-10 | 11.2 | VSNFKB-Q6: NF-kappaB | NF-kappaB | 1.00E-10 | 18.4 | VSNFKB-01: NF-kappaB binding site | NF-kappaB | 1.00E-10 | 19.4 |
| 12 | Jaspar Irf-1 | IRF-1 interferon regulatory factor 1 | 1.00E-10 | 16.3 | VSNFKB-01: NF-kappaB binding site | NF-kappaB | 1.00E-10 | 19.4 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 |
| 13 | Jaspar ISRE-01: ISRE | interferon-stimulated response element | 0.0022 | 5.1 | VSNFKB-01: NF-kappaB binding site | NF-kappaB | 1.00E-10 | 18.4 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 |
| 14 | Jaspar Irf-2 | IRF-2 interferon regulatory factor 2 | 1.53E-6 | 9.2 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 |
| 15 | Jaspar ISRE-01: ISRE | interferon-stimulated response element | 0.0022 | 5.1 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 | VSNFKPAB50-01: NF-kappaB | NF-kappaB (p50) | 0.0005 | 19.4 |

(Generes upregulated more than 1.5-fold were analyzed using the JASPAR and TRANSFEC databases. Results with a p-value of less than 0.05 are shown. % input refers to the number of gene promoters bearing the specific motif compared to total number screened.

doi:10.1371/journal.pone.0037498.t003
the members of the NF-kB/REL family. To confirm the results, we also searched the TRANSFAC database and similarly found over-representation of binding sites for the members of the NF-kB/REL family among the promoters of the genes induced by K13 in BCBL1 cells. We next repeated the analysis with our previously published HUVEC dataset. There were 10 sites that were over-represented in JASPAR database using stringent parameters (p<0.01, FDR<0.10), while 14 binding sites were over-represented in TRANSFAC (p<0.01, FDR<0.15) database. Similar to the BCBL1 dataset, NF-kB/REL binding sites were again over-represented among the promoters of the genes induced by K13 in HUVEC in both databases. Thus, consistent with our published studies [9,27] and the results of the pathway analysis, NF-kB/REL is the major transcription factor responsible for gene induction by K13 in both BCBL1 and HUVECs. However, in addition to NF-kB, several other TF binding sites were also over-represented among the promoters of genes upregulated by K13.

Validation of in silico results

We validated our gene array data by determining mRNA expression of twenty-five highly expressed genes (TRADD, TNFSRF25, TNFSRF1B, RANTES/CCL5, SELE, CXCL10, BID, NFKB1A, NFKB1, LTbR, VCAM, LMNB2, CTSS, ALCAM, IL15, IL9, IL6, BIRC3, CIITA, HLADMB, IFNG, HLADQB1, HLADQ1, GAS2 and CD74) belonging to the cytokine, NF-kB, cell death, cell adhesion and antigen processing pathways (Table S5). We found a good correlation with the expression of the above as determined by real-time RT-PCR and gene array data (Figure 2). As a control for the reliability of qRT-PCR experiments, the mRNA expression of various housekeeping genes such as GAPDH, 18S, GNBL, and β-2-microglobulin was

Figure 2. Validation of gene array data by qRT-PCR. (A) Twenty five genes from NF-kB, cytokine, and inflammatory pathways were randomly selected and their relative mRNA levels in mock and 4OHT-treated vector and K13-ERTAM-expressing BCBL1 cells were examined using qRT-PCR. Real-time PCR reactions were performed in triplicate and the data presented as fold change mean ± S.E in target gene expression (*p<0.05; Student’s t-test). (B) Pearson Correlation coefficient between gene expression array and real time PCR showed a significant agreement (Correlation coefficient 0.88; p<0.0001). doi:10.1371/journal.pone.0037498.g002
investigated and their expression level in both mock cells as well as K13-ERTAM-expressing cells remained unaltered (data not shown).

K13-induced NF-κB pathway is known to be effectively blocked by Bay-11-7082 and arsenic trioxide [13,39]. To examine the role of the NF-κB pathway in the expression of K13-regulated genes in BCBL1 cells, we studied the effect of Bay-11-7082 and arsenic trioxide on 4OHT induced gene induction in BCBL1-K13-ER cells by qRT-PCR analysis. As shown in Figure 3, pretreatment of BCBL1 K13-ERTAM cells with Bay-11-7082 and arsenic trioxide effectively blocked the induction of TNFSRF1B, SELE, CXCL10, NFKB1A, LMNB2, IL6, IFNG, CIITA, CTSS and CD74 genes by 4OHT.

Mechanism of K13-induced RANTES/CCL5 upregulation

To study the mechanism by which K13 upregulates the expression of genes in BCBL1 cells in greater detail, we selected RANTES/CCL5 as a representative example since its expression was also induced by K13 in HUVECs. RANTES is an important protein involved in immunoregulatory, inflammatory and cell proliferation pathways [40], making its mechanism of upregulation by K13 of biological and clinical significance. We began by validating the results of gene expression and qRT-PCR analyses by checking the effect of K13 on RANTES expression at the protein level. As shown in Figure 4A, we confirmed that expression of RANTES was up-regulated in the supernatant of BCBL1-K13-ERTAM cells upon treatment with 4OHT, as determined by ELISA.

To investigate the mechanism by which K13 upregulates RANTES expression, human embryonic kidney 293T cells were transfected with a luciferase-based reporter construct containing the RANTES gene promoter. K13 strongly activated the RANTES promoter as compared to empty vector-transfected cells (Figure 4B). Since NF-κB pathway was identified as the major

---

**Figure 3.** NF-κB inhibitors block K13-regulated genes. BCBL1 K13-ERTAM cells were treated with two NF-κB inhibitors (2 μM Bay 11-7082 or 2 μM As2O3) for 2 hours followed by 4OHT treatment for additional 24 hours and total RNA was isolated as described in the Materials and Methods section. Nine genes were randomly picked and their relative mRNA levels were examined using real-time RT-PCR as explained in Figure 2A. doi:10.1371/journal.pone.0037498.g003
pathway induced by K13 by both the pathway analysis and JASPAR/TRANFAC database analysis, we next examined the involvement of this pathway in K13-induced RANTES transcriptional activation. For this purpose, we took advantage of a mutant of K13, K13-58AAA, which lacks the ability to activate the NF-κB pathway [7]. As shown in Figure 4C, K13-58AAA mutant failed to activate the RANTES promoter. Furthermore, K13-induced RANTES activity was effectively blocked by two phosphorylation-resistant mutants of IκBα (IκBαSS32/36AA and IκBαD) (Figure 4D-E) that are known to block the NF-κB pathway [27], and by treatment with chemical inhibitors of the NF-κB pathway, including Bay-11-7082 [13], IKK inhibitor VI [41], PS1145 [42] and arsenic trioxide [39]. Collectively, these results confirm the involvement of the NF-κB pathway in K13-induced up-regulation of RANTES.

Figure 4. K13-induced NF-κB activity is critical for the activation of RANTES. (A) K13-induced up regulation of RANTES at protein level. Cellular supernatant from BCBL1 vector and K13-ER<sup>TAM</sup> cells treated with and without 4OHT were collected and used to measure the secretion of RANTES by ELISA. The values shown are averages (mean ± SE) of one representative experiment out of three in which the level of RANTES secretion was measured in triplicate. (B–C) 293T cells were transfected with an empty vector, wild-type K13 (B) or K13-58AAA (C) (250 ng/well) along with a RANTES promoter-driven luciferase constructs (75 ng/well) and a pRSV/LacZ (β-galactosidase) reporter construct (75 ng/well), and the reporter assay performed as described under the Materials and Methods section. (D) Dominant-negative mutants of IκBα (IκBαD and IκBαSS32/36AA) block K13-induced RANTES promoter activity. 293T cells were transfected either with the indicated plasmids and reporter assay performed as described above. The amount of IκBα mutant plasmids (500 ng/well) was five times the amount of vector or K13 (100 ng/well) plasmid and the total amount of transfected DNA was kept constant by adding empty vector. (E) Pharmacologic inhibitors of NF-κB block K13-induced RANTES promoter activation. 293T cells were transfected with an empty vector or a vector encoding K13 along with RANTES-Luc and pRSV/LacZ reporter constructs. Approximately 3 hours after transfection, cells were treated with dimethyl sulfoxide (vehicle) or the indicated compounds for 18 hours before cell lysis and measurement of reporter activities. Reporter assay was performed as described for Figure 4B–C.

doi:10.1371/journal.pone.0037498.g004

Biological consequences of K13-induced gene expression

We have previously shown that ectopic expression of K13 in Rat1 fibroblast cells stimulates cellular proliferation [8] and its shRNA-mediated silencing results in a block in cell proliferation [9]. To study the biological consequences of K13 in PEL, we studied the effect of 4OHT on cell cycle progression in BCBL1-K13-ER<sup>TAM</sup> cells. As shown in Figure 5A, 4OHT treatment of serum-starved BCBL1-K13-ER<sup>TAM</sup> cells resulted in an increase in cells in the G1-phase as compared to the untreated cells (24.6% vs 14.8%), suggesting that K13 stimulates cell-cycle progression from G1 to S phase. Treatment with 4OHT had no significant effect on cell cycle progression in the BCBL1-vector cells (data not shown). The stimulatory effect of 4OHT on G1 to S phase transition was blocked by treatment with Bay-11-7082, thereby confirming the role of K13-induced NF-κB activation in this process (Figure 5A).
In addition to stimulating the proliferation of KSHV-infected cells, K13 induced cytokine upregulation could contribute to the pathogenesis of KSHV-associated malignancies by stimulating the survival and proliferation of neighboring uninfected cells by acting in a paracrine fashion. To test this hypothesis, we examined the ability of conditioned supernatant from untreated and 4OHT-treated BCBL1-K13-ERTAM cells to support the survival of murine T1165 plasmacytoma cell line that requires IL6 for survival and proliferation [43]. As shown in Figure 5B, survival of T1165 cells was reduced to approximately 6% when grown in IL6-free medium for 72 hours. The addition of conditioned supernatant from untreated or 4OHT-treated BCBL1-vector cells afforded minor protection against IL6-withdrawal-induced cell death (approximately 25% cell survival), reflecting low-level constitutive IL6 secretion from the BCBL1 cells. The conditioned supernatant from untreated BCBL1-K13-ERTAM cells similarly resulted in only partial rescue from IL6-withdrawal-induced cell death (Figure 5B). In contrast, conditioned supernatant from 4OHT-treated BCBL1-K13-ERTAM cells markedly improved the survival (77% survival) of T1165 cells, reflecting upregulation of IL6 secretion by induction of K13 activity (Figure 5B). The survival advantage conferred by the conditioned medium from 4OHT-treated BCBL1-K13-ERTAM cells, however, disappeared if the cells were treated with both 4OHT and Bay-11-7082, confirming a role of K13-induced NF-κB in this process (Figure 5B).

### Discussion

PEL is a rare subset of non-Hodgkin’s lymphoma found in patients with HIV/AIDS that predominantly grows in the body cavities as neoplastic effusions, usually without a contiguous tumor mass [44]. Morphologically, PEL shows features that bridge immunoblastic and anaplastic large-cell lymphomas, and frequently displays some degree of plasma cell differentiation [45]. We and others have demonstrated that K13 plays a key role in constitutive NF-κB activity observed in PEL cells [9,46] and is an oncogenic protein which contribute to lymphoproliferative disorders [11,47,48]. In the present investigation, we provide a comprehensive picture of global transcriptional changes induced by K13 in PEL-derived BCBL1 cells. BCBL1 cells are infected with KSHV but express very little K13 endogenously and have negligible constitutive NF-κB activity [24,49]. As such, we chose BCBL1 cells as a physiological relevant cell line to study the effect of ectopic K13 expression on gene expression in lymphoid cells.

We observed that K13 upregulated the expression of a number of NF-κB-responsive genes in BCBL1 cells. This observation was confirmed by GSEA, qRT-PCR as well as analysis of JASPER and TRANSFAC databases. Nuclear factor-κB (NF-κB) is a critical transcription factor involved in the regulated expression of several genes involved in the inflammatory and immune response [50]. Although many dimeric forms of NF-κB have been described, the classical NF-κB complex is a heterodimer of the p65/RelA and p50 subunits and is found in most cells in association with a family
of inhibitory proteins called IkBα [51,52]. We have previously shown that K13 activates the classical NF-κB pathway by activating a multi-subunit IkB kinase (IKK) complex [53], which contains two catalytic subunits, IKK1/IKKα and IKK2/IKKβ, and a regulatory subunit, NEMO/IKKγ [52,54]. Activation of the IKK complex by K13 results in phosphorylation of IkB proteins which leads to their ubiquitination and proteasomal-mediated degradation, allowing the classical NF-κB subunits to enter the nucleus and turn on the expression of their target genes [53]. We have also shown that K13 can also activate an alternate NF-κB pathway [9] that involves IKK1/IKKα-mediated phosphorylation of p100/NFKBz and its slow proteasome-mediated processing into the active p52/p49 subunit that culminates in a kinetically slower nuclear translocation of the p52-RelB NF-κB complex [54,55]. Interestingly, NFKBz/p100 and RelB, the two NF-κB subunits involved in alternate NF-κB pathway, were among the genes upregulated by K13 in BCBL1 cells (Table 1). These results suggest that, in addition to IKK1-induced p100 phosphorylation, transcriptional upregulation of NFKBz and RelB may also contribute to the activation of the alternate NF-κB pathway by K13.

We also observed significant upregulation of TNFAIP3 (A20) and NFKB1A (IkBa) by K13 in BCBL1 cells. A20 is a deubiquitinating enzyme that is known to act as a tumor suppressor in several subtypes of non-Hodgkin and Hodgkin lymphomas [56]. We have recently demonstrated that A20 blocked K13-induced NF-κB activity and K13-induced upregulation of proinflammatory cytokines in a negative-feedback fashion [49]. A20 was also shown to block K13-induced cellular transformation [49]. In addition to A20, K13 upregulated the expression of NFKB1A, which codes for IkBα, the negative regulator of the classical NF-κB pathway that serves to keep the p65/p50 heterodimers sequestered in an inactive state in the cytoplasm [57]. Finally, the expression of SOCS1 (suppressor of cytokine signaling 1), a negative regulator of the JAK/STAT [58] signaling was significantly induced in the K13-expressing BCBL1 cells. The uncontrolled activation of the NF-κB and JAK/STAT pathways has the potential of resulting in uncontrolled inflammatory response. Therefore, induction of A20, IkBα and SOCS1 by K13 in lymphoid cells may serve to attenuate the inflammatory response and thus help maintain a balance between the virus and the host.

In addition to the positive and negative regulators of the NF-κB pathway, expression of RANTES/CCL5 was significantly upregulated in K13-expressing BCBL1 and HUVECs. Further studies utilizing a RANTES promoter-driven luciferase reporter construct demonstrated that K13 upregulates RANTES through the NF-κB pathway. RANTES is a powerful chemotaxant for blood monocytes, memory T helper cells and eosinophils [59] and as such may contribute to the inflammatory infiltrate present in KSHV-associated malignancies. Additionally, RANTES/CCL5 has been shown to promote tumor proliferation, invasion, metastases and angiogenesis [60] [61], which may also contribute to the development of PEL and KS.

K13 also upregulated the expression of Epstein-Barr virus-induced gene-3 (EBI-3), which associates with p28 to form interleukin-27 (IL-27) or with IL-12 p35 to form IL-35. Both IL-27 and IL-35 have immunosuppressive properties [62]. In particular, IL-35 has been implicated in the suppressive function of regulatory T cells (Treg), which contributes to infection tolerance and tumor progression [62,63]. Thus, it is conceivable that K13-induced upregulation of EBI-3 may not only contribute to immune tolerance of KSHV-infected cells but also promote progression of PEL and KS via generation of Tregs with suppressive functions.

Another cytokine whose expression was upregulated by K13 in BCBL1 cells was IL-32. A recent study demonstrated that the IL-32 promoter contains NF-κB binding sites [64], which suggests that, similar to the situation with RANTES/CCL5, K13 might upregulate IL-32 through NF-κB activation. Interestingly, there is a good correlation between IL-32 levels and HIV-1 replication in lymphatic tissues and IL-32 was recently shown to play an immunosuppressive role in lymphatic tissues during HIV-1 infection [65]. IL-32 was shown to induce the expression of immunosuppressive molecules IDO (indole-amine-2,3-dioxygenase) and Ig-like transcript 4 in immune cells, which not only block immune activation but also impair host defenses [65]. It is conceivable that the dampening of anti-viral immune response by K13-induced IL-32 induction may enhance HIV-1 replication and persistence, thereby resulting in a synergistic interaction between HIV-1 and KSHV.

A comparative analysis of K13-induced genes in BCBL1 and HUVEC revealed that although K13 primarily induced NF-κB responsive genes in both cell types, there were significant qualitative and quantitative differences. In particular, genes belonging to cytokines and chemokines were highly and differentially induced in HUVEC but not in the BCBL1 cells, with few exceptions, such as RANTES/CCL5 and CXCL10. The differential and robust induction of proinflammatory chemokines and cytokines by K13 in HUVEC may account for the presence of intense inflammatory infiltrate in KSHV associated KS. The underlying reasons for the differential gene induction by K13-induced NF-κB in the two cell types are not clear, but may reflect the presence of lineage-specific positive and negative regulators or epigenetic alterations. It is interesting to note in this regard that SOCS1, a negative regulator of the cytokine signaling, was upregulated only in the K13-expressing BCBL1 cells.

In addition to the NF-κB pathway, genes belonging to a number of other pathways, such as cytokine, death, inflammatory, and antigen processing pathways, were found to be enriched among K13-expressing BCBL1 cells and HUVECs. Similarly, JASPER and TRANSFAC databases revealed the enrichment of a number of transcriptional factors in addition to NF-κB among the promoters of genes upregulated by K13 in BCBL1 and HUVECs. However, there is considerable overlap among the genes induced by the different signaling pathways and transcription factors. In particular, NF-κB pathway is well known for its ability to induce genes belonging to cytokine, death, antigen processing and inflammatory pathways, and to work in concert with other transcription factors, such as AP1 [66]. Therefore, it is conceivable that enrichment of genes belonging to signaling pathways other than the NF-κB pathway may simply reflect this overlap. We also observed that K13 upregulates the expression of a number of chemokines and cytokines, especially in HUVECs, which could work in an autocrine/paracrine fashion to activate a number of secondary signaling pathways and transcription factors, providing an alternative explanation for our results. Studies are in progress to delineate the role of K13 in activation of signaling pathways other than the NF-κB pathway.

PEL display a gene expression profile that is distinct from all non-Hodgkin lymphomas of immunocompetent hosts and AIDS-associated NHL [67]. The gene expression profile of PEL has been defined as plasmablastic as it shares features of both immunoblasts and plasma cells [67]. Interestingly, increased expression of a number of genes found to be induced by K13 in the BCBL1 cells in the present study, including SOCS1, TNFAIP3, NFKB1A,
LTB, IL2RG, RELB, RRAD, CCL5, PHLDA2, CHITA, RGS1 and FAS, have been associated with the plasmablastic phenotype in human lymphomas [60]. K13 also upregulated the expression of IL6, a plasma cell growth factor that has been also shown to stimulate the proliferation of PEL cells [69]. PEL cells are typified by their lack of expression of B cell markers [48]. Interestingly, CD19, a B cell marker, was one of the genes downregulated by K13 in BCBL1 cells. Finally, PEL cells are defined by the overexpression of genes involved in inflammation, cell adhesion and invasion, which is believed to contribute to their presentation in the body cavities [2]. Interestingly, in the present study, we observed significant upregulation of genes belonging to all the above categories upon K13 expression. Thus, K13 may contribute to the unique gene expression profile and presentation in body cavities that are characteristic of KSHV-associated PEL.

**Acknowledgments**

We thank Dr. Robert Schel-Diner (Northwestern University) for the RANTES reporter constructs, Dr. Steven Cole (University of California at Los Angeles) for helpful discussions regarding transcription factor analysis and Dr. Ciaren Graham for a critical review of the manuscript.

**Author Contributions**

Conceived and designed the experiments: PMC VP. Performed the experiments: VP HM. Analyzed the data: VP HM PMC. Contributed reagents/materials/analysis tools: VP PMC. Wrote the paper: VP PMC.

---

**References**

1. Carbone A, Gloghini A (2007) HHV-8-associated lymphoma: state-of-the-art review. Acta Haematol 117: 129–131.
2. Jenner R, Maillard K, Cattini N, Weiss RA, Boshoff C, et al. (2003) Kaposi’s sarcoma-associated herpes-virus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100: 10399–10404.
3. Ganem D (2006) KSHV infection and the pathogenesis of Kaposi’s sarcoma. Annual Review of Pathology-Mechanisms of Disease 1: 273–296.
4. Chaudhary PM, Nicholas J (2008) Molecular Biology of Human Herpesvirus 8. Principles of Transformation and Pathogenesis. Basel: Karger. pp 186–210.
5. Dittmer D, Lagunoff M, Rettenmeier A, Staikos K, Haase A, et al. (1998) A cluster of cavities that are characteristic of KSHV-associated PEL.

---

**Supporting Information**

**Table S1** List of primers used for qRT-PCR (mRNA expression). (DOC)

**Table S2** Summary of differentially regulated gene clusters in 4OHT-treated K13-ER<sup> TAM </sup>-transduced BCBL1 cells. (DOC)

**Table S3** List of common differentially regulated genes in HUVECs and BCBL1 cells. (DOC)

**Table S4** List of genes upregulated >20 fold in HUVECs dataset. (DOCX)

**Table S5** Summary of representative genes corresponded to pathways identified by GSEA analysis and validated in qRT-PCR. (DCX)

---

**PLoS ONE | www.plosone.org 14 May 2012 | Volume 7 | Issue 5 | e37498**
K13-Induced Genes in PEL

29. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B (2004) JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 32: D91–94.

30. Ho Sai SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW (2007) ChIPSUM: an integrated tool for analysis of regulatory motif over-representation. Nucleic Acids Res 35: W245–252.

31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.

32. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.

33. Punj V, Matta H, Schamus S, Tamewitz A, Anyang B, et al. (2010) Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-164a. Oncogene 29: 1835–1844.

34. Sinha S, Adler AS, Field Y, Chang HY, Segal E (2008) Systematic functional characterization of cis-regulatory motifs in human core promoters. Genome Res 18: 477–488.

35. Warner JB, Filippakos AA, Jaeger SA, He FS, Lin J, et al. (2008) Identification of mammalian regulatory motifs' target genes and functions. Nat Methods 5: 347–353.

36. Roeder HG, Kanhere A, Manke T, Vingron M (2007) Predicting transcription factor affinities to DNA from a biophysical model. Bioinformatics 23: 134–140.

37. Hestand MS, van Galen M, Villerius MP, van Ommen GJ, den Dunnen JT, et al. (2008) CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics 9: 495.

38. Kim SY, Kim Y (2006) Genome-wide prediction of transcriptional regulatory elements using gene expression and promoter analysis data. BMC Bioinformatics 7: 330.

39. Matta H, Sun Q, Moses G, Chaudhary PM (2003) Molecular genetic analysis of Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. J Clin Invest 121: 1141–1153.

40. Matta H, Gopalakrishnan R, Punj V, Yi H, Suo Y, et al. (2011) A20 is induced by Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner. J Biol Chem 286: 21555–21564.

41. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18: 2195–2224.

42. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu Rev Immunol 18: 621–663.

43. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, et al. (2002) The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the Ikappa B Kinase Complex. J Biol Chem 277: 13574–13574.

44. Colon JL, Dallas D (2002) Two pathways to NF-kappaB activation and their role in innate and adaptive immunity. Trends Immunol 23: 208–208.

45. Pomerantz JT, Baltimore D (2002) Two pathways to NF-kappaB. Molecular Cell 10: 693–695.

46. Homa N, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, et al. (2009) TNFalpha is an oncogene that functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114: 2467–2475.

47. Chiao EJ, Miyamoto S, Verma IM (1996) Auto-regulation of I kappaB alpha activity. Proc Natl Acad Sci U S A 93: 29–32.

48. Yoshikawa H, Matusbara K, Qian GS, Jackson P, Groopman JD, et al. (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hematopoietic carcinoma and shows growth-suppression activity. Nat Genet 29: 29–35.

49. Crawford A, Angelosanto JM, Nadwodny KL, Blackburn SD, Wherry EJ (2011) A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog 7: e1002090.

50. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557–563.

51. Safford N, Richard B, Holaway H, Osadl O, Charnau N, et al. (2011) Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans 39: 1649–1653.

52. Tong H, Miyazaki Y, Yamazaki M, Hara H, Waldmann H, et al. (2010) Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 48: 1573–1577.

53. Smith AJ, Toledo CM, Wietgrefe SW, Duan L, Schacker TW, et al. (2011) The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection. J Immunol 186: 6195–6202.

54. Crawford A, Angelosanto JM, Nadwodny KL, Blackbur SD, Wherry EJ (2011) A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog 7: e1002090.

55. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, et al. (2002) The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the Ikappa B Kinase Complex. J Biol Chem 277: 13574–13574.

56. Pan X, Cao H, Lu J, Shu X, Xiong X, et al. (2011) Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 48: 1573–1577.

57. Smith AJ, Toledo CM, Wietgrefe SW, Duan L, Schacker TW, et al. (2011) The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection. J Immunol 186: 6195–6202.

58. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Rev Immunol 2: 344–352.